Lv1
100 积分 2022-10-10 加入
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
3个月前
已完结
Genetics of Atypical Hemolytic Uremic Syndrome (aHUS)
3个月前
已完结
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
5个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
5个月前
已完结
Ways to fit a PK model with some data below the quantification limit
5个月前
已完结
Handling Data Below the Limit of Quantification in Mixed Effect Models
5个月前
已完结
OP0025 FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY
5个月前
已完结
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
5个月前
已完结
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
5个月前
已完结
The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy
5个月前
已完结
皖公网安备34019202002308
